Axovia Therapeutics is working on a treatment for Bardet-Biedl Syndrome (BBS) called AXV-101, a gene therapy for people with mutations in the BBS1 gene. The first clinical trial of AXV-101 is now recruiting. It will investigate whether the treatment is safe and whether it can slow down retinal degeneration, a common issue in BBS.

The trial is open to children and young people aged 4 to 17 with BBS1 mutations and retinal degeneration. In England, it is taking place at Moorfields Eye Hospital in London.

Find out more about this trial: AXV-101 BBS1 gene therapy trial (ISRCTN96250868)